Showing 101 - 120 results of 42,079 for search '(( 50 ((ppm decrease) OR (a decrease)) ) OR ((( 5 mean decrease ) OR ( a non decrease ))))', query time: 0.72s Refine Results
  1. 101
  2. 102
  3. 103
  4. 104

    Time course of best-corrected visual acuity (BCVA) in recurrence and non-recurrence groups. by Yasuyuki Sotani (20114144)

    Published 2025
    “…In the non-recurrence group, CRT improved from 482.5 ± 112.8 to 294.7 ± 65.3, 302.0 ± 68.0, 284.7 ± 55.4, 285.3 ± 70.2, 265.2 ± 65.0, and 266.1 ± 78.2 μm at 1, 3, 6, 12, 24, and 36 months, respectively (Kruskal-Wallis test, p < 0.001; <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0332941#pone.0332941.g006" target="_blank">Fig 6</a>).…”
  5. 105
  6. 106
  7. 107
  8. 108
  9. 109
  10. 110
  11. 111
  12. 112
  13. 113

    A summary of the included study characteristics. by Zahra Tajik (20752452)

    Published 2025
    “…There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …”
  14. 114
  15. 115
  16. 116

    Table 1_Previous treatment decreases efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer.doc by Lei Wang (6656)

    Published 2025
    “…Background<p>Pralsetinib is a selective RET inhibitor. The ARROW trial revealed that RET fusion-positive non-small-cell lung cancer (NSCLC) can benefit from pralsetinib with tolerable adverse events (AEs). …”
  17. 117
  18. 118

    CM-DWM-EC chart using 30% decrease in the mean for the E(KeV). by Shumaila Nisar (20114256)

    Published 2024
    “…<p>CM-DWM-EC chart using 30% decrease in the mean for the E(KeV).</p>…”
  19. 119
  20. 120